Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial-Reference-Cited by-同舟云学术

Pembrolizumab versus investigator-choice chemotherapy for metastatic triple-negative breast cancer (KEYNOTE-119): a randomised, open-label, phase 3 trial

Published:2021-04 Issue:4 Volume:22 Page:499-511
ISSN:1470-2045
Container-title:The Lancet Oncology
language:en
Short-container-title:The Lancet Oncology

Author:

Winer Eric P,Lipatov Oleg,Im Seock-Ah,Goncalves Anthony,Muñoz-Couselo Eva,Lee Keun Seok,Schmid Peter,Tamura Kenji,Testa Laura,Witzel Isabell,Ohtani Shoichiro,Turner Nicholas,Zambelli Stefania,Harbeck Nadia,Andre Fabrice,Dent Rebecca,Zhou Xuan,Karantza Vassiliki,Mejia Jaime,Cortes Javier

Publisher

Elsevier BV

Subject

Oncology

Reference25 articles.

1. Triple-negative breast cancer: clinical features and patterns of recurrence;Dent;Clin Cancer Res,2007

2. TBCRC 001: randomized phase II study of cetuximab in combination with carboplatin in stage IV triple-negative breast cancer;Carey;J Clin Oncol,2012

3. Molecular subtypes of breast cancer in relation to paclitaxel response and outcomes in women with metastatic disease: results from CALGB 9342;Harris;Breast Cancer Res,2006

4. Platinum-based chemotherapy in metastatic triple-negative breast cancer: the Institut Curie experience;Staudacher;Ann Oncol,2011

5. First-line bevacizumab in combination with chemotherapy for HER2-negative metastatic breast cancer: pooled and subgroup analyses of data from 2447 patients;Miles;Ann Oncol,2013

Cited by 304 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy and Safety of Pembrolizumab Monotherapy or Combined Therapy in Patients with Metastatic Triple-negative Breast Cancer: A Systematic Review and Meta-Analysis of Randomized Controlled Trials;Current Gene Therapy;2025-02

2. Ginseng extract (Ginsenoside RG3) combined with STING agonist reverses TAM/M2 polarization to inhibit TNBC evolution;Industrial Crops and Products;2024-12

3. Evolving immunotherapeutic solutions for triple-negative breast carcinoma;Cancer Treatment Reviews;2024-11

4. Implications of nanotherapeutic advancements to leverage multi-drug resistant breast cancer: The state-of-the-art review;Journal of Drug Delivery Science and Technology;2024-10

5. Results from the randomized KEYNOTE-355 study of pembrolizumab plus chemotherapy for Asian patients with advanced TNBC;npj Breast Cancer;2024-09-12